Dexamethasone Phosphate 4 mg/ml Solution for Injection
Authorisation PA0822/201/001 · Pfizer Healthcare Ireland Unlimited Company
- Licence holder
- Pfizer Healthcare Ireland Unlimited Company (all products →)
- Active substance
- Dexamethasone sodium phosphate
- Clinical trials
- 344 clinical trials →
- Dosage form
- Solution for injection
- Route of administration
- Intravenous use
- ATC codes
- H02AB, H02AB02
- First authorised
- 28/07/1986
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Dexamethasone sodium phosphate: supply and approvals
22 authorised products on the HPRA list contain Dexamethasone sodium phosphate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- Dexamethasone Sodium Phosphate Injection: in shortage, updated 18 Nov 2026
- Germany (BfArM)
- 1 supply notice, e.g. Dexamethason 1,5 mg Jenapharm (1 Jun 2026 to 29 Jan 2027)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 40 years (since 28 July 1986). The HPRA list marks it as marketed in Ireland.
Other medicines with Dexamethasone sodium phosphate in Ireland
10 other products on the HPRA list contain Dexamethasone sodium phosphate, from 10 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Dexamethasone Phosphate Krka 4 mg/ml solution for injection/infusion | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| Dexamethasone phosphate Noridem 4 mg/mL Solution for injection | Noridem Enterprises Limited | National authorisation (PA) | Marketed |
| Dexamethasone phosphate Teva 4 mg/ml solution for injection | Teva B.V. | National authorisation (PA) | Marketed |
| Dexsol 2 mg/ 5 ml Oral Solution | Taw Pharma (Ireland) Limited | National authorisation (PA) | Marketed |
| Dexamethasone Phosphate 4 mg/ml solution for injection | hameln pharma GmbH | National authorisation (PA) | Not marketed |
| Dexamethasone phosphate 4 mg/ml solution for injection | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Not marketed |
| Dexamethasone phosphate 4 mg/ml solution for injection/infusion | AS Kalceks | National authorisation (PA) | Not stated |
| Dexamethasone phosphate 4mg/ml Solution for Injection or Infusion | Pinewood Laboratories Limited | National authorisation (PA) | Not marketed |
| Dexeta 1.37 mg/ml eye drops, solution in single dose container | SIFI S.p.A. | National authorisation (PA) | Not marketed |
| Dexliq 4 mg/ml Oral Solution | Laboratoires CTRS | National authorisation (PA) | Not marketed |
Other substances in ATC group H02AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 8 other active substances share the group H02AB with this product:
Hydrocortisone (9) · Prednisolone (6) · Methylprednisolone acetate (4) · Methylprednisolone (4) · Dexamethasone (2) · Lidocaine hydrochloride (1) · Dexamethasone acetate (1) · Hydrocortisone sodium phosphate (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Pfizer Healthcare Ireland Unlimited Company holds 109 products on the HPRA list, with 63 different active substances; 104 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.